MediPoint: Total Hip Replacement - US Analysis and Market Forecasts

News provided by

Aug 28, 2013, 01:40 ET

NEW YORK, Aug. 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Total Hip Replacement - US Analysis and Market Forecasts
http://www.reportlinker.com/p01605716/MediPoint-Total-Hip-Replacement---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

MediPoint: Total Hip Replacement - US Analysis and Market Forecasts

Summary

Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR).

GlobalData's analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products' articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share.

The mature market in the design of hip replacement products has led to a shift in the focus of developing orthopedic implants. Orthopedic surgery in the hip has become more minimally invasive unlike that of the past, with smaller incision sizes, the development of computer-navigated arthroplasty systems and even bone-preserving techniques such as resurfacing. This report addresses the various unmet needs, presents the current technology and the drivers for the future and market growth in the US. Adoption rates are examined, as well as the decision-makers, in order capture market share.

Scope

- An overview of arthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized US THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for THR
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon

Reasons to buy

- Understand the trends shaping and driving the US THR Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US THR market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in US THR market landscape? Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 16
1.2 List of Figures 26
2 Introduction 30
2.1 Catalyst 31
3 Disease Overview 33
3.1 Anatomy and Physiology 33
3.2 Pathophysiology 34
3.2.1 Overview 34
3.2.2 Osteoarthritis 34
3.2.3 Rheumatoid Arthritis 35
3.2.4 Post-traumatic Arthritis 36
3.2.5 Osteonecrosis 36
3.2.6 Injury 36
3.2.7 Bone Tumors 37
3.2.8 Other Diseases 37
3.3 Clinical Presentation 38
3.4 Clinical Outcomes 39
3.4.1 Overview 39
3.4.2 Conservative Therapy 41
3.4.3 Hip Arthroscopy 41
3.4.4 Hip Arthrodesis 42
3.4.5 Hemiarthroplasty (Partial) 43
3.4.6 Core Decompression 43
3.4.7 Hip Osteotomy 44
3.4.8 Resection Arthroplasty 44
3.4.9 Primary Total Hip Replacement 45
3.4.10 Revision Total Hip Replacement 47
3.4.11 Resurfacing Arthroplasty 48
3.4.12 Computer-Navigated Hip Replacement 49
3.5 Surgical Approaches 49
3.5.1 Anterolateral Approach 51
3.5.2 Posterior Approach 51
3.5.3 Direct Anterior Approach 52
3.5.4 Minimally Invasive Approaches 52
3.6 Epidemiology 53
3.6.1 US 54
3.7 Economic Impact 55
3.7.1 US 56
4 Competitive Assessment 58
4.1 Overview of Historical Designs 58
4.2 Marketed Products 59
4.2.1 Global Market Share 59
4.2.2 Primary Total Hip Replacement 61
4.2.3 Product Profiles by Company 61
5 Unmet Needs 203
5.1 Long-Term Clinical Data 203
5.2 Need for Continued Materials Research 203
5.3 Bearings 205
5.4 Refocus of Pipeline Products 206
5.5 Renewal of Resurfacing 207
5.6 Addressing the Learning Curve for Tier II Surgeons 208
5.7 Need for Cost Containment 210
5.8 Centralization 211
5.9 National Joint Registry 211
6 Pipeline Products 213
6.1 Overview 213
6.2 Primary Total Hip Pipeline Products 213
6.2.1 Exactech LPI Prime Hip System 213
6.2.2 EnduRo Bone-preserving Hip Stem 214
6.2.3 Deltamotion Acetabular Cup System 214
6.2.4 NovoSource Hip Implant 215
7 Industry Overview 216
7.1 Procedure Volumes 216
7.1.1 US 217
7.2 Market Access 218
7.2.1 US 218
7.3 Reimbursement Trends 221
7.3.1 US 221
7.4 Regulatory Issues/Recalls 223
7.4.1 DePuy Hip Replacement Recall 224
7.4.2 Stryker Hip Replacement Recall 224
7.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 224
7.4.4 Zimmer Durom® Acetabular Component 225
7.4.5 Biomet Hip Replacement Complications 225
7.4.6 Wright Medical Conserve Hip Implant 225
7.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 225
7.5 Mergers & Acquisitions / Key Partnerships 226
7.5.1 Medtronic Acquires China Kanghui Holdings 226
7.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 226
7.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 227
7.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 227
7.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 227
7.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 228
8 Company Profiles 229
8.1 B. Braun 229
8.1.1 Overview 229
8.1.2 Portfolio Assessment 230
8.1.3 SWOT Analysis 230
8.2 Biomet Orthopedics 231
8.2.1 Overview 231
8.2.2 Portfolio Assessment 232
8.2.3 SWOT Analysis 235
8.3 Corentec Co. Ltd. 236
8.3.1 Overview 236
8.3.2 Portfolio Assessment 236
8.3.3 SWOT Analysis 237
8.4 Corin 237
8.4.1 Overview 237
8.4.2 Portfolio Assessment 238
8.4.3 SWOT Analysis 239
8.5 DePuy Synthes International 240
8.5.1 Overview 240
8.5.2 Portfolio Assessment 241
8.5.3 SWOT Analysis 244
8.6 Exactech 244
8.6.1 Overview 244
8.6.2 Portfolio Assessment 245
8.6.3 SWOT Analysis 247
8.7 Iconacy Orthopedic Implants LLC 247
8.7.1 Overview 247
8.7.2 Portfolio Assessment 248
8.7.3 SWOT Analysis 248
8.8 Implantcast GMBH 249
8.8.1 Overview 249
8.8.2 Portfolio Assessment 249
8.8.3 SWOT Analysis 251
8.9 JRI Orthopaedics 251
8.9.1 Overview 251
8.9.2 Portfolio Assessment 252
8.9.3 SWOT Analysis 253
8.10 Kyocera 253
8.10.1 Overview 253
8.10.2 Portfolio Assessment 254
8.10.3 SWOT Analysis 255
8.11 Limacorporate S.P.A 255
8.11.1 Overview 255
8.11.2 Portfolio Assessment 256
8.11.3 SWOT Analysis 257
8.12 Medacta 258
8.12.1 Overview 258
8.12.2 Portfolio Assessment 258
8.12.3 SWOT Analysis 259
8.13 Medtronic 260
8.13.1 Overview 260
8.13.2 Portfolio Assessment 261
8.13.3 SWOT Analysis 262
8.14 NovoSource Inc. 262
8.14.1 Overview 262
8.14.2 Portfolio Assessment 263
8.14.3 SWOT Analysis 264
8.15 Peter Brehm GMBH 264
8.15.1 Overview 264
8.15.2 Portfolio Assessment 265
8.15.3 SWOT Analysis 265
8.16 Serf Dedienne Santé 266
8.16.1 Overview 266
8.16.2 Portfolio Assessment 267
8.16.3 SWOT Analysis 268
8.17 Smith & Nephew 268
8.17.1 Overview 268
8.17.2 Portfolio Assessment 269
8.17.3 SWOT Analysis 271
8.18 Stelkast 271
8.18.1 Overview 271
8.18.2 Portfolio Assessment 272
8.18.3 SWOT Analysis 272
8.19 Stryker 273
8.19.1 Overview 273
8.19.2 Portfolio Assessment 274
8.19.3 SWOT Analysis 275
8.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 276
8.20.1 Overview 276
8.20.2 Portfolio Assessment 276
8.20.3 SWOT Analysis 277
8.21 Tornier N.V. 278
8.21.1 Overview 278
8.21.2 Portfolio Assessment 279
8.21.3 SWOT Analysis 281
8.22 Wright Medical 281
8.22.1 Overview 281
8.22.2 Portfolio Assessment 282
8.22.3 SWOT Analysis 284
8.23 United Orthopedic Corporation 285
8.23.1 Overview 285
8.23.2 Portfolio Assessment 285
8.23.3 SWOT Analysis 286
8.24 Zimmer Holdings Inc. 287
8.24.1 Overview 287
8.24.2 Portfolio Assessment 288
8.24.3 SWOT Analysis 290
8.25 Other Companies 291
9 Market Drivers, Opportunities and Barriers 292
9.1 Market Drivers 292
9.1.1 Prevalence Rise 292
9.1.2 Expanding Indications 294
9.1.3 Availability and Lack of Long-Term Clinical Data 295
9.1.4 Fracture Incidence 295
9.1.5 Patient Demand and Awareness 295
9.2 Opportunities 296
9.2.1 Revision Surgery 296
9.2.2 Emerging Markets 296
9.2.3 Continued Materials Research 297
9.2.4 Corporate Promotions and Teaching Seminars 298
9.2.5 Advancement towards Cost Reduction 298
9.3 Market Barriers 299
9.3.1 Market Barriers 299
10 Country Outlooks & Forecasts 303
10.1 US Market Analysis 303
11 Appendix 307
11.1 Abbreviations 307
11.2 Bibliography 308
11.3 Report Methodology 325
11.3.1 Overview 325
11.3.2 Coverage 325
11.3.3 Secondary Research 326
11.3.4 Forecasting Methodology 327
11.3.5 Primary Research – Key Opinion Leader Interviews 328
11.3.6 Expert Panel Validation 328
11.4 Physicians and Specialists Included in this Study 329
11.4.1 Dr. Alessandro Aprato 329
11.4.2 Dr. Fran Channa 329
11.4.3 Joseph Daniel FRCS MS (Orth) 329
11.4.4 Dr. Alejandro Gonzalez Della Valle 329
11.4.5 Dr. Moussa Hamadouche 329
11.4.6 Dr. Sheng-Li Huang and Xi-Jing He 329
11.4.7 Dr. Ayumi Kaneuji 329
11.4.8 Dr. Yuichi Mitani 329
11.4.9 Dr. Ning Lu 330
11.4.10 Dr. Deepak Saini 330
11.4.11 Dr. Lafayette Lage 330
11.4.12 Dr. Christoph Zilkens 330
11.5 About the Authors 331
11.5.1 Analysts 331
11.5.2 Global Head of Healthcare 332
11.6 About MediPoint 333
11.7 About GlobalData 333
11.8 Disclaimer 333

1.1 List of Tables

Table 1: Clinical Symptoms and Descriptions 38
Table 2: Advantages and Disadvantages of Hip Resurfacing 48
Table 3: Surgical Approaches Comparison 49
Table 4: Direct and Indirect Costs of Arthritis 55
Table 5: Bicontact Universal Hip System (B. Braun) 63
Table 6: Clinical Studies Bicontact Universal Hip System (B. Braun) 64
Table 7: SWOT Bicontact Universal Hip System 64
Table 8: Excia Hip Stem (B. Braun) 66
Table 9: Clinical Studies Excia Hip Stem (B. Braun) 67
Table 10: SWOT Excia Hip Stem 67
Table 11: Metha® Short Hip Stem (B. Braun) 69
Table 12: Clinical Studies Metha® Short Hip Stem (B. Braun) 70
Table 13: SWOT Metha® Short Hip Stem 70
Table 14: TRJ Cementless Hip Endoprosthesis System (B. Braun) 72
Table 15: SWOT TRJ Cementless Hip Endoprosthesis System 73
Table 16: Plasmacup SC Acetabular Cup (B. Braun) 74
Table 17: Balance Femoral Component (Biomet) 76
Table 18: Clinical Studies Balance Femoral Component (Biomet) 76
Table 19: SWOT Balance Femoral Component 77
Table 20: Bi-Metric Femoral Components (Biomet) 78
Table 21: Clinical Studies Bi-Metric Femoral Components (Biomet) 78
Table 22: SWOT Bi-Metric Femoral Components 79
Table 23: Bio-Moore II Hip System (Biomet) 80
Table 24: Clinical Studies Bio-Moore II Hip System (Biomet) 80
Table 25: SWOT Bio-Moore II Hip System 81
Table 26: Generation 4 Polished Hip System (Biomet) 82
Table 27: SWOT Generation 4 Polished Hip System 82
Table 28: Integral Porous Primary Hip System (Biomet) 84
Table 29: Clinical Studies Integral Porous Hip System (Biomet) 84
Table 30: SWOT Integral Porous Hip System Femoral Components 85
Table 31: Mallory Femoral Component (Biomet) 86
Table 32: Clinical Studies Mallory Femoral Component (Biomet) 87
Table 33: SWOT Mallory Femoral Component 87
Table 34: Progressive Total Hip System (Biomet) 88
Table 35: SWOT Progressive Total Hip System 89
Table 36: Rx 90 Smooth Primary Femoral Component (Biomet) 90
Table 37: SWOT Rx 90 Smooth Primary Femoral Component 90
Table 38: Stanmore Hip System (Biomet) 92
Table 39: Clinical Studies Stanmore Hip System (Biomet) 92
Table 40: SWOT Stanmore Hip System 93
Table 41: Taperloc and Balance Microplasty Hip Stems (Biomet) 94
Table 42: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) 94
Table 43: SWOT Taperloc and Balance Microplasty Hip Stems 95
Table 44: Acetabular Systems (Biomet) 95
Table 45: Bencox Stems (Corentec Co. Ltd) 97
Table 46: Clinical Studies Bencox Stems (Corentec Co. Ltd) 97
Table 47: SWOT Bencox Stems 98
Table 48: Bencox Acetabular Systems (Corentec Co. Ltd.) 99
Table 49: MetaFix (Corin) 100
Table 50: SWOT MetaFix 100
Table 51: MiniHip (Corin) 102
Table 52: SWOT MiniHip 102
Table 53: MRP-Titan (Corin) 104
Table 54: SWOT MRP-Titan 104
Table 55: TaperFit (Corin) 106
Table 56: SWOT TaperFit 106
Table 57: Trinity Acetabular System (Corin) 108
Table 58: Cenator Acetabular Cup (Corin) 109
Table 59: Cementless Systems (DePuy Synthes) 111
Table 60: Clinical Studies Cementless Systems (DePuy Synthes) 111
Table 61: SWOT DePuy Synthes Cementless Systems 112
Table 62: Cemented Systems (DePuy Synthes) 113
Table 63: Clinical Studies Cemented Systems (DePuy Synthes) 113
Table 64: SWOT DePuy Synthes Cemented Systems 113
Table 65: DePuy Synthes Acetabular Systems (DePuy Synthes) 115
Table 66: AcuMatch Femoral Stems (Exactech) 116
Table 67: Clinical Studies AcuMatch Femoral Stems (Exactech) 117
Table 68: SWOT AcuMatch Femoral Stems 117
Table 69: Novation Femoral Stems (Exactech) 119
Table 70: Clinical Studies Novation Femoral Stems (Exactech) 119
Table 71: SWOT Novation Femoral Stems 120
Table 72: Exactech Acetabular Systems (Exactech) 120
Table 73: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 122
Table 74: SWOT i-Hip Total Hip Implant 122
Table 75: EcoFit Femoral Stem (Implantcast GMBH) 124
Table 76: Aida Short Femoral Stem (Implantcast GMBH) 125
Table 77: AJS Hip System (Implantcast GMBH) 126
Table 78: DiaLoc Hip Stem (Implantcast GMBH) 127
Table 79: LOAD SHIFT Hip Stem (Implantcast GMBH) 128
Table 80: Ceraco Hip Stem (Implantcast GMBH) 129
Table 81: IC Straight Stem Type I and Type II (Implantcast GMBH) 130
Table 82: Bicana Hip Stem (Implantcast GMBH) 131
Table 83: SWOT Implantcast GMBH Femoral Stems 131
Table 84: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 133
Table 85: Aeon Hip System (JRI Orthopaedics) 134
Table 86: SWOT Aeon Hip System 134
Table 87: Furlong Hip System and Evolution System (JRI Orthopaedics) 135
Table 88: Clinical Studies Furlong Hip System (JRI Orthopaedics) 136
Table 89: SWOT Furlong Hip System and Evolution System 136
Table 90: Limacorporate Cementless Femoral Stems (Limacorporate SPA) 138
Table 91: SWOT Limacorporate Cementless Femoral Stems 138
Table 92: Cemented and Cementless Stems (Limacorporate SPA) 140
Table 93: SWOT Cemented and Cementless Stems (Limacorporate SPA) 140
Table 94: Limacorporate Acetabular Systems 141
Table 95: Cemented and Cementless Stems (Medacta) 143
Table 96: SWOT Medacta Stems 143
Table 97: Acetabular Cups and Femoral Heads (Medacta) 144
Table 98: Helicon Hip System (TGM Medical, wholly owned by Medtronic) 145
Table 99: SWOT Helicon Hip System 146
Table 100: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) 148
Table 101: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) 148
Table 102: SWOT Peter Brehm Products 149
Table 103: Libra and Sagittal EVL (Serf Dedienne Santé) 151
Table 104: SWOT Libra and Sagittal EVL 151
Table 105: Acetabular Cups (Serf Dedienne Santé) 153
Table 106: Echelon and Synergy (Smith & Nephew) 155
Table 107: SWOT Echelon and Synergy 155
Table 108: Anthology Hip System (Smith & Nephew) 156
Table 109: SWOT Anthology Hip System 157
Table 110: CPCS and Spectron Hip System (Smith & Nephew) 158
Table 111: SWOT CPCS and Spectron Hip System 158
Table 112: Emperion and SMF Modular Stems (Smith & Nephew) 159
Table 113: SWOT Emperion and SMF Modular Stems 160
Table 114: Acetabular Cups (Smith & Nephew) 161
Table 115: ProClass Hip Stem (Stelkast) 162
Table 116: SWOT ProClass Hip Stem 162
Table 117: Progeny Hip Stem (Stelkast) 163
Table 118: SWOT Progeny Hip Stem 164
Table 119: Protract Hip Stem (Stelkast) 165
Table 120: SWOT Protract Hip Stem 165
Table 121: Provident Hip Stem (Stelkast) 166
Table 122: SWOT Provident Hip Stem 167
Table 123: Acetabular Cups (Stelkast) 169
Table 124: Cementless Stems (Stryker) 171
Table 125: SWOT Cementless Stems 171
Table 126: Cemented Stems (Stryker) 172
Table 127: SWOT Cemented Stems 173
Table 128: Acetabular Systems (Stryker) 174
Table 129: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 175
Table 130: SWOT Diamond Total Hip Implant 175
Table 131: Linea Stem (Tornier N.V.) 177
Table 132: SWOT Linea Stem 178
Table 133: Meije Duo Stem (Tornier N.V.) 179
Table 134: SWOT Meije Duo Stem 180
Table 135: Oceane Stem (Tornier N.V.) 181
Table 136: SWOT Oceane Stem 182
Table 137: Tornier Femoral Heads (Tornier N.V.) 183
Table 138: Oceane Cup (Tornier N.V.) 184
Table 139: Tornier Dynacup (Tornier N.V.) 185
Table 140: Tornier Dual Mobility (Tornier N.V.) 186
Table 141: Perfecta Cementless and Cemented Stems (Wright Medical) 187
Table 142: SWOT Perfecta Cementless and Cemented Stems 188
Table 143: Cementless Femoral Stems (Wright Medical) 190
Table 144: SWOT Cementless Femoral Stems 191
Table 145: Cemented Femoral Stems (Wright Medical) 192
Table 146: SWOT Cemented and Cementless Femoral Stems (Wright Medical) 192
Table 147: Acetabular Systems (Wright Medical) 194
Table 148: UTF and UTF Reduced Stem (United Orthopedic Company) 195
Table 149: SWOT UTF and UTF Reduced Stem 196
Table 150: Hip U1 and U2 Stems (United Orthopedic Corporation) 197
Table 151: SWOT Acetabular Systems (United Orthopedic Corporation) 197
Table 152: Acetabular Systems (United Orthopedic Corporation) 198
Table 153: Press-Fit Stems (Zimmer Holdings Inc.) 200
Table 154: SWOT Press-Fit Stems 200
Table 155: Acetabular Systems (Zimmer Holdings Inc.) 202
Table 156: Exactech LPI Prime Hip System (Exactech) 214
Table 157: Company Profile – B. Braun 229
Table 158: B. Braun Product Portfolio 230
Table 159: SWOT Analysis – B. Braun 230
Table 160: Company Profile – Biomet Orthopedics 231
Table 161: Biomet Product Portfolio 233
Table 162: SWOT Analysis – Biomet Orthopedics 235
Table 163: Company Profile – Corentec Co. Ltd. 236
Table 164: Corentec Product Portfolio 236
Table 165: SWOT Analysis – Corentec Co. Ltd. 237
Table 166: Company Profile – Corin Group 238
Table 167: Corin Group Product Portfolio 239
Table 168: SWOT Analysis – Corin Group 239
Table 169: Company Profile – DePuy Synthes International 241
Table 170: DePuy Synthes International Product Portfolio 242
Table 171: SWOT Analysis – DePuy Synthes International 244
Table 172: Company Profile – Exactech 245
Table 173: Exactech Product Portfolio 246
Table 174: SWOT Analysis – Exactech 247
Table 175: Company Profile – Iconacy Orthopedic Implants LLC 247
Table 176: Iconacy Orthopedic Implants LLC Product Portfolio 248
Table 177: SWOT Analysis – Iconacy Orthopedic Implants LLC 248
Table 178: Company Profile – Implantcast GMBH 249
Table 179: Implantcast GMBH Product Portfolio 250
Table 180: SWOT Analysis – Implantcast GMBH 251
Table 181: Company Profile – JRI Orthopaedics 251
Table 182: JRI Orthopaedics Product Portfolio 252
Table 183: SWOT Analysis – JRI Orthopaedics 253
Table 184: Company Profile – KYOCERA Medical Corporation 254
Table 185: KYOCERA Medical Corporation Product Portfolio 254
Table 186: SWOT Analysis – KYOCERA Medical Corporation 255
Table 187: Company Profile – Limacorporate S.P.A 256
Table 188: Limacorporate S.P.A Product Portfolio 256
Table 189: SWOT Analysis – Limacorporate S.P.A 257
Table 190: Company Profile – Medacta International 258
Table 191: Medacta International Product Portfolio 259
Table 192: SWOT Analysis – Medacta International 259
Table 193: Company Profile – Medtronic 260
Table 194: Medtronic Product Portfolio 261
Table 195: SWOT Analysis – Medtronic 262
Table 196: Company Profile – NovoSource Inc. 263
Table 197: NovoSource Inc. Product Portfolio 263
Table 198: SWOT Analysis – NovoSource Inc. 264
Table 199: Company Profile – Peter Brehm GMBH 264
Table 200: Peter Brehm GMBH Product Portfolio 265
Table 201: SWOT Analysis – Peter Brehm GMBH 265
Table 202: Company Profile – Serf Dedienne Santé 266
Table 203: Serf Dedienne Santé Product Portfolio 267
Table 204: SWOT Analysis – Serf Dedienne Santé 268
Table 205: Company Profile – Smith & Nephew 269
Table 206: Smith & Nephew Product Portfolio 270
Table 207: SWOT Analysis – Smith & Nephew 271
Table 208: Company Profile – Stelkast 271
Table 209: Stelkast Product Portfolio 272
Table 210: SWOT Analysis – Stelkast 272
Table 211: Company Profile – Stryker 274
Table 212: Stryker Product Portfolio 275
Table 213: SWOT Analysis – Stryker 275
Table 214: Company Profile – Tianjin Zhengtian Medical Instrument Co. Ltd. 276
Table 215: Tianjin Zhengtian Medical Instrument Co. Ltd. Product Portfolio 277
Table 216: SWOT Analysis – Tianjin Zhengtian Medical Instrument Co. Ltd. 277
Table 217: Company Profile – Tornier N.V. 279
Table 218: Tornier N.V. Product Portfolio 280
Table 219: SWOT Analysis – Tornier N.V. 281
Table 220: Company Profile – Wright Medical 282
Table 221: Wright Medical Product Portfolio 283
Table 222: SWOT Analysis – Wright Medical 284
Table 223: Company Profile – United Orthopedic Corporation 285
Table 224: United Orthopedic Corporation Product Portfolio 286
Table 225: SWOT Analysis – United Orthopedic Corporation 286
Table 226: Company Profile – Zimmer Holdings Inc. 288
Table 227: Zimmer Holdings Inc. Product Portfolio 289
Table 228: SWOT Analysis – Zimmer Holdings, Inc. 290
Table 229: Other Companies in the Global Hip Replacement Market 291
Table 230: US Sales ($m) Forecast for THR, 2010–2019 305

1.2 List of Figures

Figure 1: Anatomy of the Hip 33
Figure 2: Treatment Paradigm for Hip Osteoarthritis 39
Figure 3: Treatment Paradigm for Hip Fractures 40
Figure 4: Hip Arthrodesis 42
Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty 46
Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally 50
Figure 7: Surgical Approach Used by Orthopedic Surgeons in North America 50
Figure 8: Population with Osteoarthritis in the US, 2010–2019 54
Figure 9: Costs Related to Total Hip Replacement 57
Figure 10: Global Market Share for Reconstructive Products, 2012 59
Figure 11: US Market Share for Hip Replacement Products, 2010 60
Figure 12: Bicontact Universal Hip System (B. Braun) 62
Figure 13: Excia Hip Stem (B. Braun) 65
Figure 14: Metha® Short Hip Stem (B. Braun) 68
Figure 15: TRJ Cementless Hip Endoprosthesis System (B. Braun) 71
Figure 16: Plasmacup SC Acetabular Cup (B. Braun) 74
Figure 17: Balance Femoral Component (Biomet) 75
Figure 18: Bi-Metric Femoral Components (Biomet) 77
Figure 19: Bio-Moore II Hip System (Biomet) 79
Figure 20: Generation 4 Polished Hip System (Biomet) 81
Figure 21: Integral Porous Primary Hip System (Biomet) 83
Figure 22: Mallory Femoral Component (Biomet) 86
Figure 23: Progressive Total Hip System (Biomet) 88
Figure 24: Rx 90 Smooth Primary Femoral Component (Biomet) 89
Figure 25: Stanmore Hip System (Biomet) 91
Figure 26: Taperloc and Balance Microplasty Hip Stems (Biomet) 93
Figure 27: Bencox Stems (Corentec Co. Ltd) 96
Figure 28: Bencox Acetabular Systems (Corentec Co. Ltd.) 98
Figure 29: MetaFix (Corin) 99
Figure 30: MiniHip (Corin) 101
Figure 31: MRP-Titan (Corin) 103
Figure 32: TaperFit (Corin) 105
Figure 33: Trinity Acetabular System (Corin) 107
Figure 34: Cenator Acetabular Cup (Corin) 109
Figure 35: Cementless Systems (DePuy Synthes) 110
Figure 36: Cemented Systems (DePuy Synthes) 112
Figure 37: DePuy Acetabular Systems (DePuy Synthes) 114
Figure 38: AcuMatch Femoral Stems (Exactech) 116
Figure 39: Novation Femoral Stems (Exactech) 118
Figure 40: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 121
Figure 41: EcoFit Femoral Stem (Implantcast GMBH) 123
Figure 42: Aida Short Femoral Stem (Implantcast GMBH) 124
Figure 43: AJS Hip System (Implantcast GMBH) 125
Figure 44: DiaLoc Hip Stem (Implantcast GMBH) 126
Figure 45: LOAD SHIFT Hip Stem (Implantcast GMBH) 127
Figure 46: Ceraco Hip Stem (Implantcast GMBH) 128
Figure 47: IC Straight Stem Type I and Type II (Implantcast GMBH) 129
Figure 48: Bicana Hip Stem (Implantcast GMBH) 130
Figure 49: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 132
Figure 50: Aeon Hip System (JRI Orthopaedics) 133
Figure 51: Furlong Hip System and Evolution System (JRI Orthopaedics) 135
Figure 52: Cemented and Cementless Stems (Limacorporate SPA) 139
Figure 53: Cemented and Cementless Stems (Medacta) 142
Figure 54: Helicon Hip System (TGM Medical wholly owned by Medtronic) 145
Figure 55: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 147
Figure 56: Libra and Sagitta EVL (Serf Dedienne Santé) 150
Figure 57: Acetabular Cups (Serf Dedienne Santé) 152
Figure 58: Echelon and Synergy (Smith & Nephew) 154
Figure 59: Anthology Hip System (Smith & Nephew) 156
Figure 60: CPCS and Spectron Hip System (Smith & Nephew) 157
Figure 61: Emperion and SMF Modular Stems (Smith & Nephew) 159
Figure 62: Acetabular Cups (Smith & Nephew) 160
Figure 63: ProClass Hip Stem (Stelkast) 161
Figure 64: Progeny Hip Stem (Stelkast) 163
Figure 65: Protract Hip Stem (Stelkast) 164
Figure 66: Provident Hip Stem (Stelkast) 166
Figure 67: Acetabular Systems (Stelkast) 168
Figure 68: Cementless Stems (Stryker) 170
Figure 69: Cemented Stems (Stryker) 172
Figure 70: Acetabular Systems (Stryker) 173
Figure 71: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 174
Figure 72: Linea Stem (Tornier N.V.) 176
Figure 73: Meije Duo Stem (Tornier N.V.) 178
Figure 74: Oceane Stem (Tornier N.V.) 180
Figure 75: Tornier Femoral Heads (Tornier N.V.) 182
Figure 76: Oceane Cup (Tornier N.V.) 183
Figure 77: Tornier Dynacup (Tornier N.V.) 185
Figure 78: Tornier Dual Mobility (Tornier N.V.) 186
Figure 79: Perfecta Cementless and Cemented Stems (Wright Medical) 187
Figure 80: Cementless Femoral Stems (Wright Medical) 189
Figure 81: Profemur Gladiator (Wright Medical) 191
Figure 82: Acetabular Systems (Wright Medical) 193
Figure 83: UTF and UTF Reduced Stem (United Orthopedic Corporation) 195
Figure 84: Hip U1 and U2 Stems (United Orthopedic Corporation) 196
Figure 85: Acetabular Systems (United Orthopedic Corporation) 198
Figure 86: Press-Fit Stems (Zimmer Holdings Inc.) 199
Figure 87: Acetabular Systems (Zimmer Holdings Inc.) 201
Figure 88: US Primary Hip Arthroplasty Procedure Volumes (2010–2019) 217
Figure 89: Arthroplasty Cost Breakdown With Patient Discharged Home (2007) 219
Figure 90: Medicare Payment Trend for Hip and Knee Joint Replacement, 1985–2009 223
Figure 91: US Sales ($m) Forecast for THR, 2010–2019 306

Companies Mentioned

B. Braun
Biomet Orthopedics
Corentec Co. Ltd.
Corin
DePuy Synthes International
Exactech
Iconacy Orthopedic Implants LLC
Implantcast GMBH
JRI Orthopaedics
Kyocera
Limacorporate S.P.A
Medacta
Medtronic
NovoSource Inc.
Peter Brehm GMBH
Serf Dedienne Santé
Smith & Nephew
Stelkast
Stryker
Tianjin Zhengtian Medical Instrument Co., Ltd.
Tornier N.V.
Wright Medical
United Orthopedic Corporation
Zimmer Holdings Inc.
Other Companies